drugset / Trial / NCT01262027
TKI258 for Metastatic Inflammatory Breast Cancer Patients
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to learn if dovitinib can help to control inflammatory breast cancer. The safety of this drug will also be studied.
Timeline
- Start
- 2012-01-27
- Primary completion
- 2015-11-25
- Completion
- 2015-11-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dovitinib | Small molecule | 500 mg | Oral |